ALDVI.PAALDVI.PA
Advicenne S.A. has one year to prove it can deliver on its biotech promise, and the next big test is its H1 2026 financial results on 2026-09-24. This is the company’s first major report since its recent restructuring, and the market is watching closely for signs of progress in its pipeline and financial health. The anchor price is $0.97, with a bull target of $1.45 and a bear fallback of $0.85, leaning slightly toward the bull path at 50%. The outcome will set the tone for the next phase of the company’s journey — whether it’s a step toward viability or a sign of deeper challenges.
The schedule
No catalysts on the current Expected Moves packet.